Gilead prices COVID-19 drug candidate remdesivir at $390/vial in U.S. - Reuters

4:20am PDT - June 29th, 2020    remdesivir - Reuters

Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.